Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

VERA·NASDAQ

$31.27

-7.9%
HealthcareBiotechnology

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

At a Glance

Live Snapshot
Market Cap$2.24B
EPS-4.6600
P/E Ratio-6.71
Earnings Date08/04/2026

No Dividend Yield Data

VERA has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

VERA has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

VERA has not reported any net dividends paid values in the available annual periods.

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. Dividend History

VERA · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

VERA Dividend Payment History

VERA · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
vera

Vera Therapeutics, Inc. Payout Ratio Analysis

VERA · NASDAQ
Dividends Paid
0.00
2025
Net Income
-299.62M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.